| 000 | 01691 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250514162501.0 | ||
| 264 | 0 | _c20040105 | |
| 008 | 200401s 0 0 eng d | ||
| 022 | _a1420-682X | ||
| 024 | 7 |
_a10.1007/s00018-003-3146-0 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aStüve, O | |
| 245 | 0 | 0 |
_aThe potential therapeutic role of statins in central nervous system autoimmune disorders. _h[electronic resource] |
| 260 |
_bCellular and molecular life sciences : CMLS _cNov 2003 |
||
| 300 |
_a2483-91 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAutoimmune Diseases of the Nervous System _xdrug therapy |
| 650 | 0 | 4 |
_aCell Movement _xdrug effects |
| 650 | 0 | 4 |
_aCentral Nervous System Diseases _xdrug therapy |
| 650 | 0 | 4 |
_aEncephalomyelitis, Autoimmune, Experimental _xdrug therapy |
| 650 | 0 | 4 |
_aHistocompatibility Antigens Class II _xanalysis |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHydroxymethylglutaryl-CoA Reductase Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aInflammation Mediators _xmetabolism |
| 650 | 0 | 4 |
_aLymphocyte Activation _xdrug effects |
| 650 | 0 | 4 |
_aMultiple Sclerosis _xdrug therapy |
| 650 | 0 | 4 | _aNuclear Proteins |
| 650 | 0 | 4 |
_aT-Lymphocytes _xdrug effects |
| 650 | 0 | 4 |
_aTrans-Activators _xgenetics |
| 700 | 1 | _aYoussef, S | |
| 700 | 1 | _aDunn, S | |
| 700 | 1 | _aSlavin, A J | |
| 700 | 1 | _aSteinman, L | |
| 700 | 1 | _aZamvil, S S | |
| 773 | 0 |
_tCellular and molecular life sciences : CMLS _gvol. 60 _gno. 11 _gp. 2483-91 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00018-003-3146-0 _zAvailable from publisher's website |
| 999 |
_c14362316 _d14362316 |
||